10 results on '"2019 冠状病毒病 (COVID-19)"'
Search Results
2. Initial chest CT findings in COVID-19: correlation with clinical features.
- Author
-
Shen, Zhu-jing, Lu, Nan, Gao, Lu-lu, Lv, Jian, Luo, Hua-fu, Jiang, Ji-feng, Xu, Chao, Li, Shi-ya, Mao, Ju-jiang, Li, Kai, Xu, Xiao-pei, and Lin, Bin
- Abstract
Copyright of Journal of Zhejiang University: Science B is the property of Springer Nature and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
- Published
- 2020
- Full Text
- View/download PDF
3. An overview of COVID-19.
- Author
-
Shi, Yu, Wang, Gang, Cai, Xiao-peng, Deng, Jing-wen, Zheng, Lin, Zhu, Hai-hong, Zheng, Min, Yang, Bo, and Chen, Zhi
- Abstract
Copyright of Journal of Zhejiang University: Science B is the property of Springer Nature and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
- Published
- 2020
- Full Text
- View/download PDF
4. Gastrointestinal involvement of COVID-19 and potential faecal transmission of SARS-CoV-2.
- Author
-
Song, Min, Li, Zong-lin, Zhou, Ye-jiang, Tian, Gang, Ye, Ting, Zeng, Zhang-rui, Deng, Jian, Wan, Hong, Li, Qing, and Liu, Jin-bo
- Abstract
Copyright of Journal of Zhejiang University: Science B is the property of Springer Nature and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
- Published
- 2020
- Full Text
- View/download PDF
5. Transmission risk of patients with COVID-19 meeting discharge criteria should be interpreted with caution.
- Author
-
Su, Jun-wei, Wu, Wen-rui, Lang, Guan-jing, Zhao, Hong, and Sheng, Ji-fang
- Abstract
Copyright of Journal of Zhejiang University: Science B is the property of Springer Nature and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
- Published
- 2020
- Full Text
- View/download PDF
6. Interferon-α2b spray inhalation did not shorten virus shedding time of SARS-CoV-2 in hospitalized patients: a preliminary matched case-control study
- Author
-
Chan yuan Ye, Huan Cai, Guo dong Yu, Shao rui Hao, Jianhua Hu, Shan yan Zhang, Ren Yan, Jiang shan Lian, Lin Zheng, Jiao jiao Xin, Ji Fang Sheng, Ci liang Jin, Yi da Yang, Jue qing Gu, Xiaoli Zhang, Hongyu Jia, and Ying feng Lu
- Subjects
0301 basic medicine ,medicine.medical_treatment ,Gastroenterology ,law.invention ,0302 clinical medicine ,law ,严重急性呼吸综合征冠状病毒 2 (SARS-CoV-2) ,Medicine ,General Pharmacology, Toxicology and Pharmaceutics ,Inhalation ,Articles ,Interferon (IFN) ,General Medicine ,倾向性评分 ,Intensive care unit ,Virus Shedding ,Hospitalization ,Diarrhea ,C-Reactive Protein ,030220 oncology & carcinogenesis ,medicine.symptom ,Coronavirus Infections ,Propensity score match ,China ,medicine.medical_specialty ,Pneumonia, Viral ,Interferon alpha-2 ,Antiviral Agents ,General Biochemistry, Genetics and Molecular Biology ,Betacoronavirus ,03 medical and health sciences ,Albumins ,Internal medicine ,Humans ,Viral shedding ,Propensity Score ,R184 ,Glucocorticoids ,Pandemics ,Retrospective Studies ,General Veterinary ,SARS-CoV-2 ,business.industry ,Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) ,Sodium ,Case-control study ,COVID-19 ,Retrospective cohort study ,Nasal Sprays ,干扰素 ,COVID-19 Drug Treatment ,Coronavirus disease 2019 (COVID-19) ,匹配 ,030104 developmental biology ,Nasal spray ,Case-Control Studies ,Propensity score matching ,business ,2019 冠状病毒病 (COVID-19) - Abstract
Background Currently, there are no drugs that have been proven to be effective against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Because of its broad antiviral activity, interferon (IFN) should be evaluated as a potential therapeutic agent for treatment of coronavirus disease 2019 (COVID-19), especially while COVID-19-specific therapies are still under development. Methods Confirmed COVID-19 patients hospitalized in the First Affiliated Hospital, School of Medicine, Zhejiang University in Hangzhou, China, from January 19 to February 19, 2020 were enrolled in a retrospective study. The patients were separated into an IFN group and a control group according to whether they received initial IFN-α2b inhalation treatment after admission. Propensity-score matching was used to balance the confounding factors. Results A total of 104 confirmed COVID-19 patients, 68 in the IFN group and 36 in the control group, were enrolled. Less hypertension (27.9% vs. 55.6%, P=0.006), dyspnea (8.8% vs. 25.0%, P=0.025), or diarrhea (4.4% vs. 19.4%, P=0.030) was observed in the IFN group. Lower levels of albumin and C-reactive protein and higher level of sodium were observed in the IFN group. Glucocorticoid dosage was lower in the IFN group (median, 40 vs. 80 mg/d, P=0.025). Compared to the control group, fewer patients in the IFN group were ventilated (13.2% vs. 33.3%, P=0.015) and admitted to intensive care unit (ICU) (16.2% vs. 44.4%, P=0.002). There were also fewer critical patients in the IFN group (7.4% vs. 25.0%, P=0.017) upon admission. Although complications during admission process were comparable between groups, the discharge rate (85.3% vs. 66.7%, P=0.027) was higher and the hospitalization time (16 vs. 21 d, P=0.015) was shorter in the IFN group. When other confounding factors were not considered, virus shedding time (10 vs. 13 d, P=0.014) was also shorter in the IFN group. However, when the influence of other factors was eliminated using propensity score matching, virus shedding time was not significantly shorter than that of the control group (12 vs. 15 d, P=0.206). Conclusions IFN-α2b spray inhalation did not shorten virus shedding time of SARS-CoV-2 in hospitalized patients.
- Published
- 2020
7. An overview of COVID-19
- Author
-
Bo Yang, Min Zheng, Zhi Chen, Hai hong Zhu, Xiao peng Cai, Yu Shi, Jing wen Deng, Lin Zheng, and Gang Wang
- Subjects
0301 basic medicine ,Epidemiology ,Amino Acid Motifs ,Review ,Pathogenesis ,Disease ,0302 clinical medicine ,严重急性呼吸 ,Pandemic ,综合征冠状病毒 2 (SARS-CoV-2) ,Medicine, Chinese Traditional ,General Pharmacology, Toxicology and Pharmaceutics ,education.field_of_study ,Prevention and management ,Viral Vaccine ,General Medicine ,030220 oncology & carcinogenesis ,Spike Glycoprotein, Coronavirus ,Emerging infectious disease ,Coronavirus Infections ,流行病学 ,China ,medicine.medical_specialty ,COVID-19 Vaccines ,Pneumonia, Viral ,Population ,Antiviral Agents ,General Biochemistry, Genetics and Molecular Biology ,Betacoronavirus ,03 medical and health sciences ,Protein Domains ,medicine ,Animals ,Humans ,预防及治疗 ,发病机理 ,education ,Intensive care medicine ,Pandemics ,COVID-19 Serotherapy ,General Veterinary ,SARS-CoV-2 ,business.industry ,Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) ,Immunization, Passive ,COVID-19 ,Outbreak ,Viral Vaccines ,medicine.disease ,Coronavirus disease 2019 (COVID-19) ,Pneumonia ,030104 developmental biology ,R511 ,Communicable Disease Control ,business ,2019 冠状病毒病 (COVID-19) - Abstract
Pneumonia caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection emerged in Wuhan City, Hubei Province, China in December 2019. By Feb. 11, 2020, the World Health Organization (WHO) officially named the disease resulting from infection with SARS-CoV-2 as coronavirus disease 2019 (COVID-19). COVID-19 represents a spectrum of clinical manifestations that typically include fever, dry cough, and fatigue, often with pulmonary involvement. SARS-CoV-2 is highly contagious and most individuals within the population at large are susceptible to infection. Wild animal hosts and infected patients are currently the main sources of disease which is transmitted via respiratory droplets and direct contact. Since the outbreak, the Chinese government and scientific community have acted rapidly to identify the causative agent and promptly shared the viral gene sequence, and have carried out measures to contain the epidemic. Meanwhile, recent research has revealed critical aspects of SARS-CoV-2 biology and disease pathogenesis; other studies have focused on epidemiology, clinical features, diagnosis, management, as well as drug and vaccine development. This review aims to summarize the latest research findings and to provide expert consensus. We will also share ongoing efforts and experience in China, which may provide insight on how to contain the epidemic and improve our understanding of this emerging infectious disease, together with updated guidance for prevention, control, and critical management of this pandemic.
- Published
- 2020
8. Initial chest CT findings in COVID-19: correlation with clinical features
- Author
-
Ji-feng Jiang, Bin Lin, Xiao-pei Xu, Lu-lu Gao, Shi-ya Li, Hua-fu Luo, Chao Xu, Ju-jiang Mao, Nan Lu, Jian Lv, Zhu-jing Shen, and Kai Li
- Subjects
Adult ,Male ,0301 basic medicine ,China ,medicine.medical_specialty ,Fever ,Pneumonia, Viral ,发热 ,胸部 CT ,淋巴细胞减少 ,General Biochemistry, Genetics and Molecular Biology ,Betacoronavirus ,03 medical and health sciences ,COVID-19 Testing ,0302 clinical medicine ,Internal medicine ,Pandemic ,Correspondence ,medicine ,Humans ,Lymphocyte Count ,General Pharmacology, Toxicology and Pharmaceutics ,Respiratory system ,Pandemics ,Infectivity ,General Veterinary ,biology ,Clinical Laboratory Techniques ,SARS-CoV-2 ,business.industry ,COVID-19 ,General Medicine ,Middle Aged ,biology.organism_classification ,medicine.disease ,Treatment Outcome ,030104 developmental biology ,Infectious disease (medical specialty) ,030220 oncology & carcinogenesis ,Viral pneumonia ,Etiology ,Middle East respiratory syndrome ,Female ,Radiography, Thoracic ,Coronavirus Infections ,Tomography, X-Ray Computed ,business ,2019 冠状病毒病 (COVID-19) - Abstract
In December 2019, coronavirus disease 2019 (COVID-19), a new de novo infectious disease, was first identified in Wuhan, China and quickly spread across China and around the world. The etiology was a novel betacoronavirus, the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Lu et al., 2020). On Mar. 11, 2020, World Health Organization (WHO) characterized COVID-19 as a global pandemic. As of Mar. 22, 2020, over 292 000 confirmed COVID-19 cases have been reported globally. To date, COVID-19, with its high infectivity, has killed more people than severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS) combined (Wu and McGoogan, 2020).
- Published
- 2020
9. Gastrointestinal involvement of COVID-19 and potential faecal transmission of SARS-CoV-2
- Author
-
Hong Wan, Ting Ye, Zhangrui Zeng, Zonglin Li, Jinbo Liu, Jian Deng, Gang Tian, Ye-jiang Zhou, Min Song, and Qing Li
- Subjects
0301 basic medicine ,China ,Coronavirus disease 2019 (COVID-19) ,Gastrointestinal Diseases ,Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) ,Pneumonia, Viral ,严重急性呼吸综合征冠状病毒 2 型 (SARS-CoV-2) ,Models, Biological ,General Biochemistry, Genetics and Molecular Biology ,law.invention ,03 medical and health sciences ,Betacoronavirus ,Feces ,0302 clinical medicine ,law ,Correspondence ,Environmental Microbiology ,Medicine ,Humans ,粪便传播 ,General Pharmacology, Toxicology and Pharmaceutics ,Pandemics ,General Veterinary ,business.industry ,SARS-CoV-2 ,COVID-19 ,General Medicine ,Virology ,胃肠道感染 ,Virus Shedding ,030104 developmental biology ,Transmission (mechanics) ,030220 oncology & carcinogenesis ,RNA, Viral ,business ,Coronavirus Infections ,2019 冠状病毒病 (COVID-19) - Abstract
Coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), was found initially in Wuhan, China in early December 2019. The pandemic has spread to 216 countries and regions, infecting more than 23310 000 people and causing over 800 000 deaths globally by Aug. 24, 2020, according to World Health Organization (https://www.who.int/emergencies/diseases/ novel-coronavirus-2019). Fever, cough, and dyspnea are the three common symptoms of the condition, whereas the conventional transmission route for SARS-CoV-2 is through droplets entering the respiratory tract. To date, infection control measures for COVID-19 have been focusing on the involvement of the respiratory system. However, ignoring potential faecal transmission and the gastrointestinal involvement of SARS-CoV-2 may result in mistakes in attempts to control the pandemic.
- Published
- 2020
10. Transmission risk of patients with COVID-19 meeting discharge criteria should be interpreted with caution
- Author
-
Ji fang Sheng, Wen rui Wu, Guan jing Lang, Junwei Su, and Hong Zhao
- Subjects
0301 basic medicine ,Adult ,Male ,2019-20 coronavirus outbreak ,China ,COVID-19 Vaccines ,Coronavirus disease 2019 (COVID-19) ,Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) ,Pneumonia, Viral ,Viral transmission ,Mistake ,Computed tomography ,Real-Time Polymerase Chain Reaction ,General Biochemistry, Genetics and Molecular Biology ,03 medical and health sciences ,Betacoronavirus ,0302 clinical medicine ,COVID-19 Testing ,Correspondence ,Medicine ,Humans ,General Pharmacology, Toxicology and Pharmaceutics ,Pandemics ,新型冠状病毒 (SARS-CoV-2) ,Patient discharge ,General Veterinary ,medicine.diagnostic_test ,business.industry ,Clinical Laboratory Techniques ,Reverse Transcriptase Polymerase Chain Reaction ,SARS-CoV-2 ,实时聚合酶链式反应 (RT-PCR) ,Sputum ,COVID-19 ,General Medicine ,Middle Aged ,Patient Discharge ,030104 developmental biology ,030220 oncology & carcinogenesis ,Female ,business ,Nuclear medicine ,Coronavirus Infections ,2019 冠状病毒病 (COVID-19) ,Inferior lobe - Abstract
As of Apr. 22, 2020, the World Health Organization (2020) has reported over 2.4 million confirmed coronavirus disease 2019 (COVID-19) patients and 169 151 deaths. Recent articles have uncovered genomic characteristics and clinical features of COVID-19 (Chan et al., 2020; Chang et al., 2020; Guan et al., 2020; Zhu et al., 2020), while our understanding of COVID-19 is still limited. As suggested by guidelines promoted by the General Office of National Health Commission of the People's Republic of China (2020) (from Versions 1 to 6), discharged standards for COVID-19 were still dependent on viral real-time polymerase chain reaction (RT-PCR) tests of respiratory specimens, showing that recovered COVID-19 patients with twice negative RT-PCR could meet discharge criteria. Here, we examined two cases in which nucleic acid test results were inconsistent with clinical and radiological findings, leading to suboptimal care.
- Published
- 2020
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.